Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9P0U1
UPID:
TOM7_HUMAN
Alternative names:
Translocase of outer membrane 7 kDa subunit homolog
Alternative UPACC:
Q9P0U1; O95939
Background:
Mitochondrial import receptor subunit TOM7 homolog, also known as Translocase of outer membrane 7 kDa subunit homolog, plays a crucial role in the assembly and stability of the TOM complex. It serves as a positive regulator of PRKN translocation to damaged mitochondria, primarily by stabilizing PINK1 on the outer membrane of depolarized mitochondria.
Therapeutic significance:
Understanding the role of Mitochondrial import receptor subunit TOM7 homolog could open doors to potential therapeutic strategies.